BBK's patient recruitment campaign for Parkinson's disease has been selected as a finalist for the Pharmaceutical Executive APEX Awards
It's exciting times here at BBK! We are so thrilled to be recognized for our creative work on the Cerevel TemPo Studies website; developed to inform and prescreen patients newly diagnosed with Parkinson’s disease. We've been selected as a finalist for this year’s Pharmaceutical Executive APEX Awards — the only healthcare marketing awards judged entirely by HCPs.
We are among four other finalists for the Central Nervous System (CNS) - Disease Awareness / Education (Unregulated) category.
"We are honored to be recognized by healthcare professionals who understand what it takes to build trust in the Parkinson's disease community," said Mike Schaeffer, BBK's creative director. "At BBK, we take great pride in our patient-centric approach, embracing the patient and caregiver perspectives to ensure that our clinical trial outreach resonates with potential participants."
The TemPo Studies website and the recruitment campaign took a sympathetic tone with the understanding that patients recently diagnosed, along with their loved ones, are looking to make the most of their time and quality of life in the face of this progressive disease. The TemPo studies evaluated the oral investigational drug tavapadon to see if it may help improve Parkinson’s disease symptoms that impact movement and daily activities.
Stay tuned for the winners. They will be announced in New York City on October 18th.